Advanced Institutes of Convergence Technology, Suwon, Gyeonggi-do, Korea.
Br J Cancer. 2012 Feb 28;106(5):923-30. doi: 10.1038/bjc.2012.11. Epub 2012 Jan 31.
CD151 is a member of the tetraspanin family, which interacts with laminin-binding integrins and other tetraspanins. This protein is implicated in motility, invasion, and metastasis of cancer cells, but the prevalence of CD151 expression in subtypes of breast cancers and its influence on clinical outcome remains to be evaluated.
The immunohistochemistry-based tissue microarray analysis showed that 127 (14.3%) cases overexpressed CD151 among 886 breast cancer patients. CD151 overexpression was found to be significantly associated with larger tumour size, higher nodal stage, advanced stage, absence of oestrogen receptor and progesterone receptor, and human epidermal growth factor receptor 2 overexpression. CD151 overexpression resulted in poorer overall survival (OS) (P<0.001) and disease-free survival (P=0.02), and stage II and III patients with CD151 overexpression demonstrated substantially poorer OS (P=0.0474 and 0.0169). In the five subtypes analyses, CD151 overexpression retained its adverse impact on OS in the Luminal A (P=0.0105) and quintuple-negative breast cancer (QNBC) subtypes, one subgroup of triple-negative breast cancer (P=0.0170). Multivariate analysis that included stage, subtype, and adjuvant chemotherapy showed that CD151 overexpression was independently associated with poor OS in invasive breast cancer.
CD151 overexpression may be a potential molecular therapeutic target for breast cancer, especially in QNBC subtype and more advanced stages of breast cancer.
CD151 是四跨膜蛋白家族的成员，与层粘连蛋白结合的整合素和其他四跨膜蛋白相互作用。该蛋白与癌细胞的运动性、侵袭性和转移性有关，但 CD151 在乳腺癌亚型中的表达率及其对临床结局的影响仍有待评估。
基于免疫组织化学的组织微阵列分析显示，在 886 例乳腺癌患者中，有 127 例（14.3%）病例 CD151 过表达。CD151 过表达与肿瘤体积较大、淋巴结分期较高、分期较晚、雌激素受体和孕激素受体缺失以及人表皮生长因子受体 2 过表达显著相关。CD151 过表达导致总生存（OS）（P<0.001）和无病生存（DFS）（P=0.02）较差，并且 CD151 过表达的 II 期和 III 期患者的 OS 明显较差（P=0.0474 和 0.0169）。在五个亚型分析中，CD151 过表达在 Luminal A（P=0.0105）和五重阴性乳腺癌（QNBC）亚型（三阴性乳腺癌的一个亚组，P=0.0170）中仍然对 OS 有不良影响。包括分期、亚型和辅助化疗的多变量分析表明，CD151 过表达与浸润性乳腺癌的不良 OS 独立相关。
CD151 过表达可能是乳腺癌的潜在分子治疗靶点，特别是在 QNBC 亚型和乳腺癌的更晚期。
